Posted by Michael Wonder on 10 Mar 2020
Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes
9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps.
Fiasp (insulin aspart injection), a faster acting mealtime insulin, is now approved in Canada for paediatric patients aged 2 years and above giving Canadian families managing type 1 or type 2 diabetes an effective treatment option to support optimal mealtime glucose control.
Health Canada has also expanded the approval of Fiasp (10 mL vials) to include use in insulin infusion pumps for the improvement of glycemic control.
